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that in Group 111, revealing the J-curve relation between SBP 
and the decline in MMSE scores. The relationship between 
the decline in MMSE scores and diastolic BP also showed a 
tendency of J-curve relation but failed to be significant ( P  < .09). 
Although the duration of follow-up was only 3 years, we 
revealed an association of high BP with deterioration in 
cognitive function, adding the J-curve relation between blood 
pressure and decline in cognitive function in a longitudinal 
study. Our results also support the findings of Meyer and 
 colleague^,^ which showed improvement of cognition after 
control of SBP from 135 to 150 mm Hg but decline in 
cognition after lowering SBP below the level of 135 mm Hg in 
hypertensive patients with multi-infarct dementia. In conclu- 
sion, it is worth remembering that not only high blood 
pressure, but also lower blood pressure, may be associated 
with later decline in the cognitive function of older people. 
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REHABILITATION OF THE OLDER AMPUTEE 
To the Editor: Cutson and Bongiorni’s recent review on 
rehabilitation of the geriatric lower extremity amputee’ was a 
timely reminder that age alone is no contraindication to 
successful prosthetic rehabilitation. Attention to the potential 
adverse effects of various comorbidities was highlighted, but 
a highly prevalent one was omitted from their discussion: 
vision impairment. It is interesting but not surprising that one 
of the three case summaries included in their article had 
diabetic retinopathy as a comorbidity. 
Beyond age 65 ,  the prevalence of significant vision loss 
increases progressively until it exceeds 25% in those aged 85 
or older.’ Several s t ~ d i e s ~ . ~  have demonstrated that two- 
thirds or more of blind lower extremity amputees can become 
successful prosthetic users. Geriatricians need to be aware of 
this fact lest they succumb to therapeutic nihilism when they 
encounter such patients. 
Stanley F. Wainapel, MD, MPH 
Clinical Director, Rehabilitation Medicine 
Montefiore Medical Center 
Bronx, NY 
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Editors note: The above letter was referred to Dr. Cutson, 
and her reply follows. 
In reply: We appreciate Dr. Wainapel’s interest and com- 
ments. Visual impairment is certainly a prevalent comorbid- 
ity among the older population and one to be considered in 
any physical rehabilitation endeavor. Our  review covered 
many studies spanning several decades, and visual impair- 
ment was not widely considered. 
The references provided by Dr. Wainapel illustrate the 
relative paucity of published data regarding amputee rehabil- 
itation among the visually impaired. Altner et al. report 
successful rehabilitation in nine of 12 blind lower limb am- 
putee patients, with five regaining preoperative activity level. 
Fisher reports on the process used in rehabilitation of two 
blind amputees. 
Preoperative ambulatory status is probably a better pre- 
dictor of successful prosthetic gait training than visual im- 
pairment itself; however, more information is certainly 
needed. 
Toni M .  Cutson, MD, M H S  
University of Michigan Medical Center 
Ann Arbor, MI  
NORTRIPTYLINE FOR THE TREATMENT OF 
DEPRESSION IN PROGRESSIVE SUPRANUCLEAR 
PALSY 
To the Editor: A recent report published in the Journal’ 
suggested that the use of low doses of amitriptyline may 
significantly improve the motor dysfunction of patients with 
progressive supranuclear palsy (PSP). Cholinergic function is 
impaired in PSP, and these patients may benefit from anticho- 
linergic treatment. Nonetheless, the use of high doses of 
amitriptyline (up to 200 mdday) for treatment was associ- 
ated with a number of toxic effects, including delirium.’ 
Engel suggested that “less anticholinergic antidepressant 
(e.g., nortriptyline) may be less toxic and more effective than 
amitriptyline in PSP, but this possibility has not been test- 
ed.’” 
We have tested this hypothesis in a 72-year-old woman with 
a history of progressive visual disturbances, dizziness, falls, gait 
instability, rigidity of the trunk and neck, slurred speech, dyspha- 
gia, hand tremor, mild aphasia, and marked depressive symp- 
toms (depressed mood, loss of interest and pleasure in activities 
that were normally pleasurable, fatiguability, loss of confidence, 
irritability, loss of appetite, insomnia, and recurrent thoughts of 
death). MRI brain imaging was suggestive of putamen, red nu- 
cleus, and substantia nigra damage. The patient was started on 
375 mg/day of I-dopa with no substantial improvement of the 
